Takeda Pharmaceutical has appointed Juliet Kim as President and CEO, planning three new product launches and five late-stage development projects within the next 12 months.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4502","jir_company_name":"Takeda Pharmaceutical Company Limited","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-06-24","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/06\/4502-20260624-01.pdf","jir_short_summary":"Takeda Pharmaceutical has appointed Juliet Kim as President and CEO, planning three new product launches and five late-stage development projects within the next 12 months.","jir_summary":"### Overview of Executive Personnel Changes and Corporate Strategy\nTakeda Pharmaceutical announced that following its 150th Annual General Meeting of Shareholders held on June 24, 2026, Juliet Kim officially assumed the position of President and CEO. Ms. Kim brings over 30 years of experience in global healthcare, and will lead the advancement of new business initiatives and product launches. Under the new board structure, the company aims to create value for patients and stakeholders, with plans to launch three key new products and advance five late-stage development projects.\n\n### Board of Directors and Future Direction of the Company\nThe newly appointed directors include experienced executives following the Shire acquisition and outside directors with a global perspective. The board consists of 11 members, including 8 outside directors. This composition ensures transparency and objectivity, while focusing on long-term shareholder value enhancement and innovation promotion. Ms. Kim will prioritize patient-centric R&D and the creation of innovative pharmaceuticals to achieve sustainable growth.","jir_financial_highlights":"","jir_category":"","jir_hashtags":"#TakedaPharmaceutical, #ExecutivePersonnel, #JapanStocks","jir_key_figures":"Number of new product launches planned: 3 (by 2026)\nLate-stage development projects: 5 (in progress)\nBoard composition: 11 members (including 8 outside directors)","jir_meta_title":"\u3010Takeda Pharmaceutical\u3011Juliet Kim Appointed as President and CEO \uff5c June 2026","jir_meta_description":"Takeda Pharmaceutical announced that Juliet Kim will become the new CEO in June 2026, with plans to launch three new products and advance five late-stage development projects within the next 12 months.","jir_og_title":"\u3010Takeda Pharmaceutical\u3011CEO Succession and Future Business Plans \uff5c June 2026","jir_og_description":"Takeda Pharmaceutical appoints Juliet Kim as the new CEO, promoting three new product launches and long-term growth strategies.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6852,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"executive_change","footnotes":""},"sector":[],"importance":[],"class_list":["post-68696","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n